{"component": "definition", "props": {"groups": [{"snippet": "means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.", "samples": [{"hash": "68S373CJgzz", "uri": "/contracts/68S373CJgzz#back-up-compound", "label": "Research, Development and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 32.8384668036, "published": true}, {"hash": "jIVDMjaL1N", "uri": "/contracts/jIVDMjaL1N#back-up-compound", "label": "Research, Development and Commercialization Agreement (Royalty Pharma PLC)", "score": 31.7816563997, "published": true}, {"hash": "aHrGezSDAKR", "uri": "/contracts/aHrGezSDAKR#back-up-compound", "label": "Research, Development and Commercialization Agreement (Royalty Pharma PLC)", "score": 31.7433264887, "published": true}], "snippet_links": [{"key": "with-reference-to", "type": "clause", "offset": [7, 24]}, {"key": "development-candidate", "type": "definition", "offset": [40, 61]}, {"key": "drug-product-candidate", "type": "definition", "offset": [65, 87]}, {"key": "mode-of-action", "type": "definition", "offset": [133, 147]}, {"key": "the-group", "type": "clause", "offset": [256, 265]}, {"key": "the-development", "type": "clause", "offset": [393, 408]}], "size": 8, "hash": "44fdb69a80b8b6ce717be735d43347ab", "id": 1}, {"snippet": "means [ * ].", "samples": [{"hash": "j5iRQ4neSkQ", "uri": "/contracts/j5iRQ4neSkQ#back-up-compound", "label": "Product Development and Commercialization Agreement (Exelixis, Inc.)", "score": 24.5947980835, "published": true}, {"hash": "lExE0uMiww0", "uri": "/contracts/lExE0uMiww0#back-up-compound", "label": "Product Development and Commercialization Agreement (Exelixis Inc)", "score": 18.0, "published": true}, {"hash": "2AAeb0LXa85", "uri": "/contracts/2AAeb0LXa85#back-up-compound", "label": "Cancer Collaboration Agreement (Exelixis Inc)", "score": 18.0, "published": true}], "snippet_links": [], "size": 8, "hash": "4eba7b8b8c85066765f243f194fbb7cd", "id": 2}, {"snippet": "means any Agreement Compound Controlled by a Party, which Agreement Compound exists on the Effective Date or is discovered or invented during the Term. Back-Up Compounds in existence on the Effective Date are set forth in Schedule 1.11", "samples": [{"hash": "3HZuJywoEnL", "uri": "/contracts/3HZuJywoEnL#back-up-compound", "label": "License and Collaboration Agreement (Hutchison China MediTech LTD)", "score": 32.1704312115, "published": true}, {"hash": "g5TYfTvULRw", "uri": "/contracts/g5TYfTvULRw#back-up-compound", "label": "License and Collaboration Agreement (Hutchison China MediTech LTD)", "score": 30.4072553046, "published": true}, {"hash": "idtJNVrIV8W", "uri": "/contracts/idtJNVrIV8W#back-up-compound", "label": "License and Collaboration Agreement (Hutchison China MediTech LTD)", "score": 30.3305954825, "published": true}], "snippet_links": [{"key": "agreement-compound", "type": "definition", "offset": [10, 28]}, {"key": "by-a-party", "type": "clause", "offset": [40, 50]}, {"key": "on-the-effective-date", "type": "clause", "offset": [84, 105]}, {"key": "during-the-term", "type": "clause", "offset": [135, 150]}, {"key": "in-existence", "type": "definition", "offset": [170, 182]}], "size": 6, "hash": "4923e38ce3a963ddae4791ece1240c5f", "id": 3}, {"snippet": "means [***].", "samples": [{"hash": "2PzjpFPdOff", "uri": "/contracts/2PzjpFPdOff#back-up-compound", "label": "License Agreement (Zealand Pharma a/S)", "score": 27.4558521561, "published": true}, {"hash": "dBWEkPvKG7E", "uri": "/contracts/dBWEkPvKG7E#back-up-compound", "label": "License and Collaboration Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 23.1656399726, "published": true}, {"hash": "70LRYDXz9mY", "uri": "/contracts/70LRYDXz9mY#back-up-compound", "label": "License and Collaboration Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 22.6016427105, "published": true}], "snippet_links": [], "size": 5, "hash": "42145ccc68badf480a8ed917c57dd5fc", "id": 4}, {"snippet": "means any Collaboration Compound that is designated by the JAC for further Development as a Back-Up Compound pursuant to Section 4.5.", "samples": [{"hash": "gidcnacw4NY", "uri": "/contracts/gidcnacw4NY#back-up-compound", "label": "License Agreement", "score": 31.340862423, "published": true}, {"hash": "9Y8t7ycgjSB", "uri": "/contracts/9Y8t7ycgjSB#back-up-compound", "label": "License Agreement (BeiGene, Ltd.)", "score": 26.787816564, "published": true}, {"hash": "doOslgD6o9b", "uri": "/contracts/doOslgD6o9b#back-up-compound", "label": "License Agreement (BeiGene, Ltd.)", "score": 26.7056810404, "published": true}], "snippet_links": [{"key": "collaboration-compound", "type": "definition", "offset": [10, 32]}, {"key": "further-development", "type": "definition", "offset": [67, 86]}, {"key": "section-45", "type": "clause", "offset": [121, 132]}], "size": 5, "hash": "40515c2cc66fc2e2e26ac53d2ebf0611", "id": 5}, {"snippet": "means any Collaboration Compound that has been selected as such hereunder, or any salt, solvate, prodrug form, inclusion complex or metabolite thereof.", "samples": [{"hash": "am9fTQmGnBM", "uri": "/contracts/am9fTQmGnBM#back-up-compound", "label": "Collaborative Research and License Agreement (Targacept Inc)", "score": 21.0, "published": true}, {"hash": "35vSRSeOAQ9", "uri": "/contracts/35vSRSeOAQ9#back-up-compound", "label": "Collaborative Research and License Agreement (Targacept Inc)", "score": 21.0, "published": true}, {"hash": "1zi7UiMRPDw", "uri": "/contracts/1zi7UiMRPDw#back-up-compound", "label": "Collaborative Research and License Agreement (Targacept Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "collaboration-compound", "type": "definition", "offset": [10, 32]}], "size": 5, "hash": "381a050ff3401b522c47e85ccdc41a9a", "id": 6}, {"snippet": "means, as to Taisho Activated Receptor, a subsequent CART Identified Compound developed by Taisho and/or Taisho's Licensee(s) subsequently to the preceding CART Identified Compound precedingly developed for the same or similar therapeutic indication as the preceding CART Identified Compound, that is developed after the discontinuation of the development of the preceding CART Identified Compound or that is reserved at the lower stage of the development than that of the preceding CART Identified Compound or that is simultaneously developed with the preceding CART Identified Compound with the intent to commercialize the subsequent CART Identified Compound only in the event the development of the preceding CART Identified Compound is discontinued. For the purpose of determination of such intent, a subsequent CART Identified Compound shall be deemed Subsequent Compound but not Back-Up Compound if Phase 3 Clinical Study thereof is started prior to the discontinuation of the development of the preceding CART Identified Compound.", "samples": [{"hash": "j5ehwuGvvYO", "uri": "/contracts/j5ehwuGvvYO#back-up-compound", "label": "License Agreement (Arena Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "5nRAM7wxW0a", "uri": "https://invest.arenapharm.com/static-files/83e2d8c7-2ebe-4dc1-aeeb-bf0381e025d5", "label": "invest.arenapharm.com", "score": 9.0533880903, "published": false}], "snippet_links": [{"key": "identified-compound", "type": "definition", "offset": [58, 77]}, {"key": "same-or-similar", "type": "definition", "offset": [211, 226]}, {"key": "therapeutic-indication", "type": "definition", "offset": [227, 249]}, {"key": "development-of-the", "type": "clause", "offset": [344, 362]}, {"key": "to-commercialize", "type": "definition", "offset": [604, 620]}, {"key": "in-the-event-the", "type": "clause", "offset": [666, 682]}, {"key": "for-the-purpose-of", "type": "definition", "offset": [754, 772]}, {"key": "determination-of", "type": "clause", "offset": [773, 789]}, {"key": "subsequent-compound", "type": "definition", "offset": [857, 876]}, {"key": "phase-3-clinical-study", "type": "definition", "offset": [905, 927]}, {"key": "prior-to-the", "type": "clause", "offset": [947, 959]}], "size": 4, "hash": "a3e8fb10a081ebf1647d6250cb86157d", "id": 7}, {"snippet": "means, with respect to a Leading Compound, any other Collaboration Compounds or GSK Development Compounds (as the case may be) in Development that [***].", "samples": [{"hash": "crYtqw5RzvH", "uri": "/contracts/crYtqw5RzvH#back-up-compound", "label": "Research and Development Collaboration, Option and License Agreement (Anacor Pharmaceuticals Inc)", "score": 21.8377823409, "published": true}, {"hash": "5yZvX1PfPtl", "uri": "/contracts/5yZvX1PfPtl#back-up-compound", "label": "Research and Development Collaboration, Option and License Agreement (Anacor Pharmaceuticals Inc)", "score": 21.8158795346, "published": true}, {"hash": "j2hfPCln3nF", "uri": "/contracts/j2hfPCln3nF#back-up-compound", "label": "Research and Development Collaboration, Option and License Agreement (Anacor Pharmaceuticals Inc)", "score": 21.6899383984, "published": true}], "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "leading-compound", "type": "definition", "offset": [25, 41]}, {"key": "collaboration-compounds", "type": "clause", "offset": [53, 76]}, {"key": "gsk-development-compounds", "type": "clause", "offset": [80, 105]}, {"key": "the-case", "type": "definition", "offset": [110, 118]}, {"key": "in-development", "type": "definition", "offset": [127, 141]}], "size": 3, "hash": "a3c014403088a2dbe468e14c8dbe15c0", "id": 8}, {"snippet": "means a Compound (other than the first Development Candidate) that was used in any monkey tolerability screen performed to identify the first Development Candidate.", "samples": [{"hash": "9QxSD4AkxY4", "uri": "/contracts/9QxSD4AkxY4#back-up-compound", "label": "HTT Research, Development, Option and License Agreement (Ionis Pharmaceuticals Inc)", "score": 34.3333333333, "published": true}, {"hash": "1i4E8VaaUJi", "uri": "/contracts/1i4E8VaaUJi#back-up-compound", "label": "HTT Research, Development, Option and License Agreement (Isis Pharmaceuticals Inc)", "score": 24.5947980835, "published": true}, {"hash": "5qF0j3r07h3", "uri": "https://ir.ionispharma.com/static-files/d2c36101-d448-4fc7-bfe2-8efd0e6034a7", "label": "ir.ionispharma.com", "score": 9.9623545517, "published": false}], "snippet_links": [{"key": "development-candidate", "type": "definition", "offset": [39, 60]}], "size": 3, "hash": "3bd0d0d0c647c0077db42b0b504580da", "id": 9}, {"snippet": "means a Designated Compound designated by Licensee as a Back-Up Compound pursuant to Section 3.5.2 (Back-Up Compounds).", "samples": [{"hash": "eOxKsLQ7OMS", "uri": "/contracts/eOxKsLQ7OMS#back-up-compound", "label": "Research and License Agreement (Akebia Therapeutics, Inc.)", "score": 28.3511293634, "published": true}, {"hash": "dtWNbNsDOqj", "uri": "http://ir.akebia.com/static-files/4c5e3480-e5af-4775-bc96-c8622d4e28fe", "label": "ir.akebia.com", "score": 10.1704312115, "published": false}, {"hash": "i0W7To21H6B", "uri": "https://ir.akebia.com/static-files/4c5e3480-e5af-4775-bc96-c8622d4e28fe", "label": "ir.akebia.com", "score": 9.9952087611, "published": false}], "snippet_links": [{"key": "designated-compound", "type": "definition", "offset": [8, 27]}, {"key": "by-licensee", "type": "clause", "offset": [39, 50]}, {"key": "section-352", "type": "clause", "offset": [85, 98]}], "size": 3, "hash": "4d43da6806d55a291a7df9bde7c12976", "id": 10}], "next_curs": "Cl0SV2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjkLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIZYmFjay11cC1jb21wb3VuZCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"snippet": "means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.", "title": "Back-Up Compound", "size": 168, "id": "back-up-compound", "examples": ["For the avoidance of doubt, in no event shall either Party conduct any Clinical Trial of any Agreement Compound, including any <strong>Back-Up Compound</strong>, without the prior written consent of the other Party.", "Subsequent to such designation, as applicable, any reference to the Product shall be deemed to include or to be made to a Product that contains, incorporates, comprises or is derived from a <strong>Back-Up Compound</strong>.", "In the event [**], the JSC (advised by the JDC, as appropriate) shall promptly nominate a <strong>Back-Up Compound</strong> to replace the Collaboration Compounds (such <strong>Back-Up Compound</strong>, a \u201cNew Collaboration Compound\u201d), and the Parties shall promptly meet to negotiate in good faith a definitive agreement (or amendment to this Agreement, if appropriate) that sets forth each Party\u2019s rights and obligations with respect to such New Collaboration Compound.", "The Parties shall promptly review the available data and other information and determine whether to so designate the proposed Collaboration Compound as a <strong>Back-Up Compound</strong>.", "Each Dainippon Substance, RiboGene Substance and Active Compound not selected as a Licensed Compound or Licensed <strong>Back-Up Compound</strong> and each Inactive Derived Compound shall be returned to the party having ownership thereof in accordance with Section 3.1(c).", "Until such time as the JSC determines that [*] derived from [*] the Lead Compound have met the requirements of the <strong>Back-Up Compound</strong> Profile or should otherwise [*], Portola shall apply Commercially Reasonable Efforts pursuant to the Development Plan to discover and evaluate Syk Selective Inhibitors which meet the <strong>Back-Up Compound</strong> Profile, including but not limited to [*].", "APSA may terminate the development of any Development Compound at any time upon prior notice to the DC and may at that time designate such compound as a <strong>Back-Up Compound</strong>.", "In the event such officers cannot agree on a resolution of the dispute within thirty (30) days: [********]; (f) if the dispute relates to APSA\u2019s request to select a Collaboration Compound (other than a Collaboration Compound that has already been designated as a <strong>Back-Up Compound</strong>) as a Development Compound or <strong>Back-Up Compound</strong> and Targacept\u2019s opposition to such request, the Collaboration Compound in question shall be subject to Section 5.4(a)(ii); [********].", "Either Party shall notify the other Party in writing in the event it wishes to replace BGB-283 with a specified Collaboration Compound developed hereunder as a <strong>Back-Up Compound</strong> or to Develop such Collaboration Compound as a <strong>Back-Up Compound</strong> in addition to BGB-283.", "If APSA terminates the development of any Development Compound and does not designate such compound as a <strong>Back-Up Compound</strong>, or if APSA does not act in accordance with the diligence obligations set forth in Section 3.2 with respect to a Development Compound, such compound shall be deemed to be a Terminated Compound."], "related": [["lead-compound", "Lead Compound", "Lead Compound"], ["licensed-compound", "Licensed Compound", "Licensed Compound"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["exempt-compound", "Exempt compound", "Exempt compound"], ["product-candidate", "Product Candidate", "Product Candidate"]], "related_snippets": [], "updated": "2025-07-06T21:58:29+00:00"}, "json": true, "cursor": ""}}